OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) – Opportunity Analysis and Forecasts to 2017

Publisher Name :
Date: 30-Sep-2013
No. of pages: 128

GlobalData has released its new Opportunity Analyzer report, “Nonalcoholic Steatohepatitis (NASH) – Opportunity Analysis and Forecasts to 2017”. The NASH market is currently deserted and awaits its first NASH-specific therapy. With novel mechanism of action awaiting approval such as: Genfit’s PPAR agonist, GFT505 and Intercept Pharmaceuticals/Dainippon Sumitomo Pharma’s FXR agonist, Obeticholic Acid. These compounds will race to be the first approved therapy thus claiming first in class.

Scope

  • Overview of NASH, including epidemiology, etiology, symptoms, diagnosis, pathology and disease management.
  • Analysis of the current and future market competition in the global NASH therapeutics market.
  • Pipeline analysis: comprehensive data split across Phase II/IIb, emerging trends and mechanisms of action under development, including: oral Proliferator Activated Receptor alpha, delta (PPARa,d) agonist, oral Farnesoid X Receptor (FXR) agonist, subcutaneous Lysyl Oxidase-Like 2 (LOXL2) inhibitor and subcutaneous Glucagon-like Peptide-1 (GLP-1) agonist.
  • Annualized NASH therapeutics market forecast, annual cost of therapy and treatment usage pattern data from 2012-2017.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
  • Key topics covered include strategic clinical and commercial benchmarking assessment of the pipeline and standard of care, market outlook, R&D strategies, and unmet needs for the NASH therapeutics market.

Reasons To Buy

Develop business strategies and perform superior market quantification analysis by:

  • Understanding the trends shaping and driving the global NASH Therapeutics market.
  • Understanding treatment preferences of physicians in disease state and across treatment flow.
  • Accessing market sizing, forecasts and quantified growth opportunities in the global NASH Therapeutics market till 2017.
  • Quantifying patient population in the global NASH Therapeutics market to better design product pricing & launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
  • Performing benchmarking analysis and growth opportunities against currently marketed products.
  • Identifying market entry points based on safety, efficacy, and pricing parameters.
  • Assessing competitiveness of products in market by understanding the strength and weakness of current competition.
  • Develop and design your in-licensing and out-licensing strategies by
  • Taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products.
  • Assessing strength of pipeline based on first in class and lifecycle management of products.
  • Analyze the potential impact of novel oral therapies such as Genfit’s GFT505 on the NASH treatment paradigm.
  • Track drug sales in the global NASH Therapeutics market from 2012 to 2017.
  • Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
  • What’s the next big thing in the global NASH Therapeutics market landscape? Identify, understand, and capitalize.

OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) – Opportunity Analysis and Forecasts to 2017

Table of Contents

1 Table of Contents 7
1.1 List of Tables 11
1.2 List of Figures 12

2 Introduction 13
2.1 Catalyst 13

3 Disease Overview 14
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 15
3.2 Symptoms 19

4 Epidemiology 21
4.1 Disease Background 21
4.2 Risk Factors and Comorbidities 22
4.2.1 Increased age is associated with a worsened disease progression, prognosis, and mortality 22
4.2.2 Being a male is an independent risk factor in morbidly obese NASH cases 23
4.2.3 Metabolic conditions, such as type 2 diabetes, considerably increase the risk of NASH 25
4.3 Global and Historical Trends 26
4.3.1 US 28
4.3.2 5EU 29
4.4 Forecast Methodology 31
4.4.1 Sources Used 33
4.4.2 Forecast Assumptions and Methods 35
4.4.3 Sources Not Used 38
4.5 Epidemiology Forecast of Nonalcoholic Steatohepatitis (2012-2022) 39
4.5.1 Total Prevalent Cases of Nonalcoholic Steatohepatitis 39
4.5.2 Age-Specific Prevalent Cases of Nonalcoholic Steatohepatitis 41
4.5.3 Sex-Specific Prevalent Cases of Nonalcoholic Steatohepatitis 44
4.5.4 Age-Standardized Prevalence of Nonalcoholic Steatohepatitis 45
4.6 Discussion 46
4.6.1 Conclusions on Epidemiological Trends 46
4.6.2 Limitations of the Analysis 47
4.6.3 Strengths of the Analysis 48

5 Current Treatment Options 49
5.1 Overview 49
5.2 Product Profiles - Major Off-Label Brands 52
5.2.1 Vitamin E (numerous generics) 52
5.2.2 Pioglitazone (Actos) 56

6 Unmet Needs Assessment and Opportunity Analysis 61
6.1 Overview 61
6.2 Unmet Needs Analysis 63
6.2.1 Lack of Approved Therapies 63
6.2.2 Identification of Biomarkers for Early Diagnosis and Endpoints 64
6.2.3 Physician Awareness Due to Understanding of Pathophysiology 65
6.3 Opportunity Analysis 65
6.3.1 Therapies with Targeted MOA to NASH 65
6.3.2 Better Models to Understand Drug Efficacy 65
6.3.3 Future Tool to Measure Fibrosis in NASH Patients 66

7 R&D Strategies 67
7.1 Overview 67
7.1.1 Understanding Multiple Factors of NASH 67
7.1.2 Potential for a Personalized Approach 68
7.2 Clinical Trial Design 69
7.2.1 Differences in Diagnosis, Monitoring, and Sensitive Imaging Techniques Are Needed 70
7.2.2 Patient Recruitment Issues 70
7.2.3 Appropriate Endpoints 71
7.2.4 Clinical Regulatory Guidelines 72

8 Pipeline Assessment 74
8.1 Overview 74
8.2 Promising Drugs in Clinical Development 75
8.2.1 GFT505 76
8.2.2 Obeticholic Acid (INT-747) 80
8.2.3 Simtuzumab (Formerly GS-6624) 84
8.2.4 Liraglutide (Victoza) 88
8.3 Innovative Early-Stage Approaches 92
8.3.1 Targeting Cytokines 93

9 Pipeline Valuation Analysis 95
9.1 Clinical Benchmark of Key Pipeline Drugs 95
9.2 Commercial Benchmark of Key Pipeline Drugs 98
9.3 Competitive Assessment 100
9.4 Top-Line Five-Year Forecast 101
9.4.1 US 105
9.4.2 5EU 106

10 Appendix 108
10.1 Bibliography 108
10.2 Abbreviations 116
10.3 Methodology 119
10.4 Forecasting Methodology 119
10.4.1 Diagnosed NASH Patients 119
10.4.2 Percent Drug-Treated Patients 120
10.4.3 Drugs Included in Each Therapeutic Class 120
10.4.4 Launch Dates 121
10.4.5 General Pricing Assumptions 121
10.4.6 Individual Off-Label Drug Assumptions 122
10.4.7 Pricing of Pipeline Agents 122
10.5 Physicians and Specialists Included in this Study 123
10.6 About the Authors 124
10.6.1 Author 124
10.6.2 Epidemiologist 125
10.6.3 Global Head of Healthcare 126
10.7 About GlobalData 127
10.8 Disclaimer 127

List of Tables

Table 1: Symptoms of NASH 19
Table 2: Risk Factors and Comorbidities for NASH 22
Table 3: Reported Prevalence of NASH in the US and 5EU 27
Table 4: Reported Prevalence of NAFLD in the US and 5EU 27
Table 5: 6MM, Sources of Prevalence Data Used in the NASH Epidemiological Forecast 32
Table 6: 6MM, Prevalent Cases of NASH, Ages ≥ 20 Years, Men and Women, N, Selected Years, 2012-2022 40
Table 7: 6MM, Prevalent Cases of NASH, By Age*, Men and Women, N (Row %), 2012 42
Table 8: 6MM, Prevalent Cases of NASH, Ages ≥ 20 Years, By Sex, N (Row %), 2012 44
Table 9: Off-Label Treatments for NASH 51
Table 10: Product Profile - Vitamin E 53
Table 11: Vitamin E SWOT Analysis in NASH, 2013 55
Table 12: Product Profile - Pioglitazone 57
Table 13: Pioglitazone SWOT Analysis in NASH, 2013 60
Table 14: Overall Unmet Needs in NASH - Current Level of Attainment 62
Table 15: Current Clinical Trial Design of Key Pipeline Drugs for NASH, 2013 73
Table 16: NASH - Mid-Late-Stage Pipeline, 2013 75
Table 17: Product Profile - GFT505 77
Table 18: GFT505 SWOT Analysis, 2013 79
Table 19: Product Profile - Obeticholic Acid (INT-747) 81
Table 20: Obeticholic Acid (INT-747) SWOT Analysis, 2013 83
Table 21: Product Profile - Simtuzumab 85
Table 22: Simtuzumab SWOT Analysis, 2013 87
Table 23: Product Profile - Liraglutide 89
Table 24: Liraglutide Safety Profile from the LEAD Program 90
Table 25: Liraglutide SWOT Analysis, 2013 91
Table 26: Early-Stage Pipeline Products in NASH, 2013 93
Table 27: Clinical Benchmark of Key Pipeline Drugs for NASH, 2013 97
Table 28: Commercial Benchmark of Key Pipeline Drugs for NASH, 2013 99
Table 29: Top-Line Sales Forecasts ($m) for NASH, 2012-2017 102
Table 30: Key Events Impacting Sales for NASH, 2017 103
Table 31: NASH Market: US and 5EU - Drivers and Barriers, 2012-2017 104
Table 32: Key Launch Dates 121

List of Figures

Figure 1: Two-Hit and Multiple-Hits Theories in NASH 16
Figure 2: Distinct-Hit Pathogenesis in NASH 18
Figure 3: Stages of Liver Disease 20
Figure 4: 5EU, Prevalence of NAFLD and Obesity, Ages ≥ 20 Years, Men and Women, % 30
Figure 5: 6MM, Prevalent Cases of NASH, Ages ≥ 20 Years, Men and Women, N, Selected Years, 2012-2022 40
Figure 6: 6MM, Prevalent Cases of NASH, By Age*, Men and Women, N, 2012 43
Figure 7: 6MM, Prevalent Cases of NASH, Ages ≥ 20 Years, By Sex, N, 2012 45
Figure 8: Liver Biopsy to Confirm NASH 50
Figure 9: Competitive Assessment of Mid-Stage Pipeline Agents in NASH, 2012-2017 76
Figure 10: Competitive Assessment of Mid-Stage Pipeline Agents in NASH, 2012-2017 100
Figure 11: Global Sales for NASH by Region, 2012-2017 103

  • Challenges in the Tourism Industry in Thailand
    Thailand has always been a popular tourist destination and tourism provides a major boost to the country’s economy. Bangkok, Hua Hin, Krabi, Samui, Phuket and Cha Am are some of the most attractive tourist destinations in the country. In 2012, Thailand had a very high number of arrivals. Even the number of Thai citizens who [...]
  • Future of the US Consumer Electronics Market
    The market for consumer electronics has been growing steadily. Some of the factors that are contributing to the growth in the market are technological advancement, rise in disposable income and increasing demand for new products. During 2012, consumer electronics market in the US demonstrated positive expansion, although the growth rate slowed down considerably following the [...]
  • Overview of the Global Retail Market
    The global retail industry continued to grow despite the difficult economic conditions in the world. In the fiscal year of 2011, sales-weighted, currency-adjusted revenue rose by 5.1% to $4.271 trillion for the world’s top 250 retailers. According to GRDI (Global Retail Development Index), in 2013 Brazil occupied the top spot in retail development. Chile and [...]
  • Bright Future Predicted for the Tourism Industry in Singapore
    Travel and tourism industry in Singapore has been growing at a steady rate and is considered to be a major contributor to the economic growth of the country. In 2012, Singapore’s IVA (International Visitors Arrivals) reached a record high of 14.5 million, with a growth rate of 10.1% year-on-year. In recent years, inbound travel to [...]
  • Potential of Staffing Market in United States
    The staffing industry places individuals into contract, temporary and permanent positions in firms around the world. Major staffing markets include France, Spain, Italy and Japan as well as many emerging markets. Temporary staffing around the world has been growing, but in US temporary market has been flat since 2006. The majority of staffing revenue majorly [...]
  • Graft-Versus-Host Disease (GVHD) Treatment Market worth $407 million by 2018
  • The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …

  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Asia-Pacific, Led by China, Drive the Global Methanol Industry
  • China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors. It accounts for 87.9% of Asia-Pacific’s (APAC) methanol capacity, and 51.9% of the global methanol capacity. Despite a large planned capacity increase in …

  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • Global and China Monoclonal Antibody Industry Report, 2014-2019
    Published: 21-Oct-2014        Price: US $2600 Onwards        Pages: 136
    Despite world-wide economic downturn and great changes in exchange rate, benefiting from robust market demand, global monoclonal antibody market size exceeded USD 80 billion in 2013, still one of biotech drugs with the fastest CAGR in recent years. Global blockbuster monoclonal antibody agents are still concentrated in Roche (Genentech), Amgen, AbbVie (Abbott), Johnson & Johnson, Novartis, etc. In 2013, the top 10 best-selling monoclonal antibody agents (Humira, Remicade, Enbrel, Rituxa, ......
  • Multinational Pharmaceuticals Companies in Asia Online Database
    Published: 20-Oct-2014        Price: US $1660 Onwards        
    The Multinational Pharmaceuticals Companies in Asia Online Database contains the latest available, individually researched data for 6690 senior executives at 2020 leading American, Asian, European and Middle Eastern & African multinational companies and key local companies in Asia. About the Multinational Pharmaceuticals Companies in Asia Online Database The Multinational Pharmaceuticals Companies in Asia Online Database is a powerful, cost-effective business development and research t......
  • Optical Imaging Market by Technique (Optical Coherence Tomography, Hyperspectral Imaging, Photoacoustic Tomography), Product (Imaging System, Imaging software) & by Application (Ophthalmology, Neurology, Oncology, Cardiology) – Global Forecasts to 2019
    Published: 17-Oct-2014        Price: US $4650 Onwards        Pages: 225
    Over the last decade, the optical imaging market has grown, primarily due to the widening applications of optical imaging techniques, the increased demand for safer and noninvasive imaging modalities, and a rising need to minimize the use of radiation in diagnostic imaging. The fast-growing pharmaceutical and biotechnology industries are also catalyzing the growth of the optical imaging market. In this report, the global optical imaging market is segmented by techniques, products, application......
  • 2014 Deep Research Report on Global Kinesio Tape Industry
    Published: 17-Oct-2014        Price: US $3600 Onwards        Pages: 162
    This is a professional and depth research report on Global Kinesio tape industry. The report firstly introduced Kinesio tape basic information included Kinesio tape definition classification application industry chain structure industry overview; Then introduce North America Europe Asia Rest of World Key players 2009-2014 Kinesio tape Capacity Production Price Cost Gross Production Value Gross Margin etc Data and information. And the report also listed North America Europe Asia Rest of Wor......
  • Orthopaedics: Market Prospects & Global Competition
    Published: 16-Oct-2014        Price: US $1500 Onwards        Pages: 540
    After a period of economic decline, the global orthopaedics market is beginning to show signs of recovery, thanks to a number of factors. It is now time to take stock of the opportunities and challenges that lie ahead. The orthopaedic industry has been under intense pressure since the global economic downturn, and has struggled to achieve growth amid tough market conditions. Additionally, the industry is under extreme pressure to adapt to the impact of social and economic changes. Rising case......
  • Canada Surgical Sutures Market Outlook to 2020
    Published: 15-Oct-2014        Price: US $2500 Onwards        Pages: 44
    Canada Surgical Sutures Market Outlook to 2020 Summary GlobalData’s new report, ""Canada Surgical Sutures Market Outlook to 2020"", provides key market data on the Canada Surgical Sutures market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments - Automated Suturing Devices (Reusable and Disposable Automated Suturing Devices) and Sutures (Absorbable and .Non-Absorbable Sutures). The report also provides co......
  • MediPoint: Aortic Stent Grafts – Global Analysis and Market Forecasts
    Published: 15-Oct-2014        Price: US $6495 Onwards        Pages: 260
    Aortic stent grafts are most commonly used to reinforce a weak spot in an artery, which is known as an aneurysm. The stent grafts are designed to seal tightly with the patient’s native artery above and below the aneurysm, and are used to treat abdominal aortic aneurysms as well as thoracic aortic aneurysms. Aortic aneurysms, as opposed to aneurysms found elsewhere in the body, are potentially very serious, as a burst aorta results in massive internal bleeding that can be fatal unless treated r......
  • Latest Guidebook for Conducting Medical Device Clinical Evaluation and Clinical Trial in China: From Regulations to Practices (2014 Edition)
    Published: 15-Oct-2014        Price: US $1495 Onwards        Pages: 199
    Summary China’s regulatory framework for medical devices is undergoing radical changes. The country’s new leaders have recognized that the regulations for supervision and administration of medical devices are far from perfect along with rapid population growth and thriving economy over the past 30 years. Chinese state council issued the latest “Regulations for the Supervision and Administration of Medical Devices” on February 12, 2014, which has come into force as of June 1, 2014. Bef......
  • EpiCast Report: Dyslipidemia – Epidemiology Forecast to 2023
    Published: 15-Oct-2014        Price: US $3995 Onwards        Pages: 94
    Dyslipidemia is a condition in which one or more of the serum lipid levels are abnormal. It is a well-established risk factor for cardiovascular disease, and the burden of morbidity, mortality, and medical costs arising from dyslipidemia is substantial. GlobalData epidemiologists forecast that the total prevalent cases of dyslipidemia in the 8MM will increase from 572,418,492 total prevalent cases in 2013, to 685,905,635 total prevalent cases in 2023, at an Annual Growth Rate (AGR) of 1.99%. ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs